EA201500694A1 - Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов - Google Patents

Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов

Info

Publication number
EA201500694A1
EA201500694A1 EA201500694A EA201500694A EA201500694A1 EA 201500694 A1 EA201500694 A1 EA 201500694A1 EA 201500694 A EA201500694 A EA 201500694A EA 201500694 A EA201500694 A EA 201500694A EA 201500694 A1 EA201500694 A1 EA 201500694A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active ingredients
combination
dosage form
medical form
modified
Prior art date
Application number
EA201500694A
Other languages
English (en)
Other versions
EA032456B1 (ru
Inventor
Франка Герно
Карл-Хайнц Прцикленк
Original Assignee
Хенниг Арцнаймиттель Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210113098 external-priority patent/DE102012113098A1/de
Application filed by Хенниг Арцнаймиттель Гмбх Унд Ко. Кг filed Critical Хенниг Арцнаймиттель Гмбх Унд Ко. Кг
Publication of EA201500694A1 publication Critical patent/EA201500694A1/ru
Publication of EA032456B1 publication Critical patent/EA032456B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к монолитной пероральной лекарственной форме, которая обеспечивает модифицированное высвобождение, предпочтительно продленное и отсроченное высвобождение, комбинации активных ингредиентов, обладающих свойствами растворимости, которые сильно отличаются друг от друга. Лекарственная форма содержит по меньшей мере один эмульгатор с полиалкиленоксидным структурным мотивом и по меньшей мере один агент контролируемого высвобождения. Даже активные ингредиенты с ограниченной стабильностью при хранении и другими нежелательными свойствами активных ингредиентов, дополнительно затрудняющими обработку, могут быть представлены наилучшим образом с помощью использования лекарственных форм в соответствии с настоящим изобретением. Изобретение также относится к способу изготовления лекарственной формы и ее применению.
EA201500694A 2012-12-27 2013-12-23 Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов EA032456B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE201210113098 DE102012113098A1 (de) 2012-12-27 2012-12-27 Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination
DE102013101049 2013-02-01
PCT/EP2013/077939 WO2014102253A1 (de) 2012-12-27 2013-12-23 Monolithische arzneiform zur modifizierten freisetzung einer wirkstoffkombination

Publications (2)

Publication Number Publication Date
EA201500694A1 true EA201500694A1 (ru) 2015-10-30
EA032456B1 EA032456B1 (ru) 2019-05-31

Family

ID=49911528

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500694A EA032456B1 (ru) 2012-12-27 2013-12-23 Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов

Country Status (19)

Country Link
US (1) US20150343067A1 (ru)
EP (1) EP2938328B1 (ru)
KR (1) KR102220130B1 (ru)
AU (1) AU2013369379B2 (ru)
BR (1) BR112015015483A8 (ru)
CA (1) CA2895609C (ru)
EA (1) EA032456B1 (ru)
HU (1) HUE063546T2 (ru)
IL (1) IL239670B (ru)
LT (1) LT2938328T (ru)
MX (1) MX370067B (ru)
PH (1) PH12015501487B1 (ru)
PT (1) PT2938328T (ru)
RS (1) RS64741B1 (ru)
SA (1) SA515360671B1 (ru)
SI (1) SI2938328T1 (ru)
UA (1) UA118099C2 (ru)
WO (1) WO2014102253A1 (ru)
ZA (1) ZA201505084B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2959887T (lt) * 2014-06-26 2019-03-12 Hennig Arzneimittel Gmbh&Co. Kg Vaistai galvos svaigimo, atsiradusio dėl įvairių priežasčių, gydymui
US20230218583A1 (en) 2020-04-17 2023-07-13 Honeybrains, Llc Compositions and methods for treating neuropsychiatric disorders
AU2022270208A1 (en) * 2021-05-05 2023-12-07 Lyndra Therapeutics, Inc. Gastric residence systems comprising methadone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
DE102011075354A1 (de) * 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur gezielten Freigabe von Wirkstoffen
LT2704698T (lt) * 2011-05-05 2019-11-25 Hennig Arzneimittel Gmbh&Co Kg Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui

Also Published As

Publication number Publication date
KR20150100734A (ko) 2015-09-02
PT2938328T (pt) 2023-09-26
CA2895609A1 (en) 2014-07-03
IL239670A0 (en) 2015-08-31
IL239670B (en) 2020-08-31
PH12015501487A1 (en) 2015-09-21
EP2938328B1 (de) 2023-07-05
SI2938328T1 (sl) 2023-11-30
UA118099C2 (uk) 2018-11-26
WO2014102253A1 (de) 2014-07-03
ZA201505084B (en) 2016-12-21
MX2015008462A (es) 2015-09-23
AU2013369379A1 (en) 2015-07-16
BR112015015483A8 (pt) 2019-10-22
CA2895609C (en) 2021-01-12
US20150343067A1 (en) 2015-12-03
SA515360671B1 (ar) 2022-11-13
EA032456B1 (ru) 2019-05-31
LT2938328T (lt) 2023-11-27
AU2013369379B2 (en) 2018-03-15
KR102220130B1 (ko) 2021-02-25
BR112015015483A2 (pt) 2017-07-11
RS64741B1 (sr) 2023-11-30
MX370067B (es) 2019-11-29
PH12015501487B1 (en) 2015-09-21
HUE063546T2 (hu) 2024-01-28
EP2938328A1 (de) 2015-11-04

Similar Documents

Publication Publication Date Title
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201590215A1 (ru) Макроциклические пурины для лечения вирусных инфекций
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
PH12016501122A1 (en) Delayed release compositions of linaclotide
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201490947A1 (ru) Производные пурина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
PH12015502118A1 (en) Pyridin-4-yl derivatives
IN2013MU03583A (ru)
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
PH12017501133A1 (en) Pyrazolopyridinamines
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
EA201690395A1 (ru) Стабильная фармацевтическая композиция, содержащая бисопролол и рамиприл
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.